Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Switching to Tenofovir Versus Continuing Entecavir in Chronic Hepatitis B Patients With Partial Virologic Response During Entecavir Therapy: STEEP Study (STEEP)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2014 by Korea University.
Recruitment status was  Recruiting
Gilead Sciences
Information provided by (Responsible Party):
Hyung Joon Yim, Korea University Identifier:
First received: October 17, 2012
Last updated: February 26, 2014
Last verified: February 2014
Entecavir, a potent antiviral agent, has been widely used for treatment-naïve chronic hepatitis B patients. However, about 20% of patients showed partial virologic response after 2 year of entecavir therapy (33% in HBeAg positive, 10% in HBeAg negative patients). Tenofovir is a nucleotide analogue with more potent antiviral activity. In addition, there is no cross resistance between the two drugs. Therefore it is assumed that tenofovir would be effective in the treatment of chronic hepatitis B patients who shows partial virologic response (detectable HBV DNA by real time PCR after 12 months of treatment) despite treatment with entecavir. In this study, we will compare the efficacy of switching to tenofovir with continuing entecavir in patients who shows partial virologic response to entecavir.

Condition Intervention Phase
Chronic Hepatitis B
Drug: tenofovir
Drug: entecavir
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Korea University:

Primary Outcome Measures:
  • Virologic response rate at year 1 (12 months) (HBV DNA < 20 IU/mL) [ Time Frame: up to the end of year 1 (12 months) ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • -Degree of HBV DNA reduction, mean HBV DNA, biochemical and serologic response rates, resistance, and adverse events at year 1 [ Time Frame: up to the end of year 1 (12 months) ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 110
Study Start Date: April 2013
Estimated Study Completion Date: December 2015
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: entecavir
standard drugs
Drug: entecavir
entecavir 0.5 mg qd
Other Name: entecavir(baraclude) 0.5 mg qd
Active Comparator: tenofovir
study drugs
Drug: tenofovir
tenofovir 300 mg qd
Other Name: tenofovir (viread)


Ages Eligible for Study:   19 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. CHB patients (positive HBsAg more than 6 months)
  2. Age 19 years old
  3. HBeAg positive or negative patients
  4. Patients receiving entecavir 0.5 mg more than 12 months
  5. Detectable HBV DNA by real time PCR (HBV > 60 IU/mL)
  6. Compensated liver function (Child-Pugh-Turcotte score ≤7, prothrombin time 3 sec above ULN or INR ≤1.5, serum albumin >3 g/dL, total bilirubin <2.5 mg/dL, no history of variceal bleeding, diuretics or ascites requiring paracentesis, hepatic encephalopathy)

Exclusion Criteria:

  1. History of treatment with nucleotide analogue
  2. Detectable entecavir resistant mutation by RFMP
  3. Decompensated cirrhosis (CTP score >7)
  4. Patients with HCC
  5. Seropositivity to HCV, HDV or HIV
  6. Pregnant and lactating woman
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01711567

Contact: Hyung Joon Yim, M.D. 82-31-412-5583
Contact: Sang Jun Suh, M.D. 82-31-412-4926

Korea, Republic of
Korea University Ansan Hospital Recruiting
Ansan, Gyeonggi-do, Korea, Republic of, 425-707
Contact: Hyung Joon Yim, M.D.    82-31-412-5583   
Contact: Sang Jun Suh, M.D.    82-31-412-4926   
Principal Investigator: Hyung Joon Yim, M.D.         
Sponsors and Collaborators
Korea University
Gilead Sciences
Principal Investigator: Hyung Joon Yim, M.D. Korea University
  More Information

Responsible Party: Hyung Joon Yim, Associate professor, Korea University Identifier: NCT01711567     History of Changes
Other Study ID Numbers: STEEP study 
Study First Received: October 17, 2012
Last Updated: February 26, 2014
Health Authority: Korea: Food and Drug Administration

Keywords provided by Korea University:
Chronic Hepatitis B

Additional relevant MeSH terms:
Hepatitis A
Hepatitis, Chronic
Hepatitis B
Hepatitis B, Chronic
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Hepadnaviridae Infections
DNA Virus Infections
Antiviral Agents
Anti-Infective Agents
Reverse Transcriptase Inhibitors
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Retroviral Agents
Anti-HIV Agents processed this record on October 21, 2016